EMD Millipore and Samsung BioLogics have signed an MOU (Memorandum of Understanding) for a strategic alliance on the biopharmaceutical business. The alliance is intended to encompass a long-term supply agreement in which EMD Millipore will provide raw materials for biopharmaceutical manufacturing.
Dr. Udit Batra, President and CEO of EMD Millipore, and Benoit Gourdier, head of EMD Millipore’s Process Solutions Asia, were present at the signing ceremony held at Samsung BioLogics’ headquarters in Korea. “Our latest partnership in the biopharmaceutical sector will further strengthen the great relationship Merck KGaA and Samsung have built in other business areas for the past years. It will also help us support Samsung’s initiative in the CMO and biopharmaceutical field,” said Dr. Batra.
EMD Millipore will become an essential raw material supplier for Samsung BioLogics’ 30KL facility as well as its new 150KL facility that is expected to be completed in 2015 at Songdo, Incheon, Korea.
“Samsung BioLogics is delighted to develop a strategic alliance with EMD Millipore, which will not only provide us a stable supply of crucial raw materials but also bring mutual advantages for both companies’ long-term business strategies and competitiveness in the biopharmaceutical industry,” said Dr. TH Kim, President and CEO of Samsung BioLogics.
